Formulation and Specifications: Capsules: 10mg, 25mg
Indications: Primary and relapsed refractory multiple myeloma.
Key points for rational drug use:
1. The drug has myelosuppressive effect, and the patient’s blood routine needs to be monitored after application.
For patients suitable for autologous stem cell transplantation, no more than 4 courses of treatment containing lenalidomide are recommended prior to transplantation.
Bortezomib has synergistic effects with lenalidomide.
4. Dose reduction is required in myeloma patients with renal impairment.
5. Long-term application increases the risk of second tumors.
6. Hematocrit and rash are common adverse effects of lenalidomide, and the rest include deep vein thrombosis.
7. The risk of deep vein thrombosis and pulmonary embolism is significantly higher in patients with multiple myeloma treated with lenalidomide in combination with dexamethasone. Signs and symptoms due to thrombosis need to be closely monitored, and prophylactic anticoagulation is recommended in combination with a high risk of thrombosis.
8. There may be embryo-reproductive toxicity and contraception should be observed during use. There are potential effects on growth and development in children.
※9. Follicular cell lymphoma (approved indications in other countries worldwide).
※10. POEMS syndrome (Phase I-II clinical study data only).
※11. Light chain amyloidosis (Phase I-II clinical study data only).
※12. MGRS (Phase I-II clinical study data only).
※13. del(5q) IPSS score for low-risk/intermediate risk 1 myelodysplastic syndrome (approved indications in other countries worldwide).